The Medical University of Silesia in Katowice has become a research partner assessing the impact of tuberculosis vaccination against SARS-CoV-2 infection among health care workers in Poland during the COVID-19 pandemic.
The research team consists of scientists from the Silesian Medical University, the Collegium of Medical Sciences of the University of Rzeszów, the Hospital of St. Louis, the S. Żeromski Hospital in Krakow, the Bielański Hospital and Prague Hospital in Warsaw. The project was co-financed by the Medical Research Agency as part of a fast track project supporting the development of effective methods of diagnosis and treatment of coronavirus.
The data obtained during the study will help determine whether the tuberculosis vaccine, which has been produced and used for years in Poland, elicits an immune response to combat viral infections, including SARS-CoV-2 in a pandemic situation. The vaccine given as part of the project has never been tested in this respect.
